Kahn Swick & Foti Continues Investigation into Humacyte Inc. Officers and Directors

The law firm Kahn Swick & Foti, LLC (KSF) announced on August 21, 2026, that it is continuing its investigation into the officers and directors of Humacyte, Inc. (NasdaqGS: HUMA). The announcement was made by Charles C. Foti, Jr., Esq., a partner at KSF and former Attorney General of Louisiana.

Specifics regarding the reasons for the investigation or its scope have not yet been made public. It remains unclear whether this inquiry pertains to a class-action lawsuit or another form of legal action. KSF has a history of involvement in significant legal cases.

Humacyte is a biotechnology company focused on developing tissue-engineered vascular grafts. The company aims to provide alternatives for patients with damaged or blocked blood vessels.

Further developments in the coming weeks and months will likely shed more light on the investigation and its potential impact on Humacyte's stock performance and operations.